- Investing Ideas
- /
- Global Pharmaceuticals & Biotech High Return On Equity, Low Debt
Global Pharmaceuticals & Biotech High Return On Equity, Low Debt
UPDATED Jul 03, 2022
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
55 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PFEPfizer | US$52.31 | 1.4% | 31.7% | US$293.5b | US$57.00 | PE11.6x | E-18.0% | 3.1% | ||
| MRKMerck | US$92.42 | -0.8% | 17.6% | US$233.7b | US$96.59 | PE16.8x | E11.8% | 3.0% | ||
| NOVNNovartis | CHF80.33 | -0.3% | -5.0% | CHF174.5b | CHF91.19 | PE7.5x | E2.8% | 3.7% | ||
| REGNRegeneron Pharmaceuticals | US$595.40 | -1.2% | 2.0% | US$64.2b | US$679.24 | PE8.1x | E-3.2% | n/a | ||
| 1177Sino Biopharmaceutical | HK$5.27 | 10.0% | -28.1% | HK$92.8b | HK$7.77 | PE5.8x | E-38.4% | 1.4% | ||
| MEDPMedpace Holdings | US$149.60 | -2.7% | -16.8% | US$4.8b | US$133.00 | PE24x | E13.4% | n/a | ||
| 2030Daan Gene | CNÂ¥17.98 | 3.5% | -10.5% | CNÂ¥24.1b | n/a | PE6.1x | n/a | 6.2% | ||
| ROVILaboratorios Farmaceuticos Rovi | €57.65 | -3.1% | -2.1% | €3.2b | €76.77 | PE17.3x | E10.3% | 1.7% | ||
| 300841Chengdu Kanghua Biological Products | CNÂ¥118.27 | 10.4% | -34.1% | CNÂ¥15.6b | CNÂ¥158.78 | PE18.4x | E27.8% | 0.8% | ||
| CHEMMChemoMetec | kr.763.50 | -5.3% | -8.6% | kr.13.3b | n/a | PE101.3x | S35.3% | 0.5% | ||
| 500674Sanofi India | ₹6,382.70 | -0.8% | -17.6% | ₹146.7b | ₹8,278.50 | PE14.2x | n/a | 2.8% | ||
| DVAXDynavax Technologies | US$12.96 | 5.1% | 30.9% | US$1.6b | US$25.75 | PE15.7x | E-25.3% | n/a | ||
| 6547Medigen Vaccine Biologics | NT$193.50 | -7.4% | -18.9% | NT$42.6b | n/a | PE29.9x | n/a | n/a | ||
| 300639Guangdong Hybribio BiotechLtd | CNÂ¥22.27 | 2.3% | 6.7% | CNÂ¥9.4b | n/a | PE8.2x | E-19.8% | 1.0% | ||
| A096530Seegene | â‚©35,050.00 | -5.9% | -57.4% | â‚©1.7t | â‚©55,666.67 | PE3.3x | E-41.7% | 2.9% | ||
| PHMPharma Mar | €68.50 | 4.8% | -10.7% | €1.2b | €80.40 | PE13.6x | E23.9% | 0.9% | ||
| 300158Shanxi Zhendong PharmaceuticalLtd | CNÂ¥6.77 | -0.9% | -12.1% | CNÂ¥6.8b | n/a | PE2.8x | n/a | 41.4% | ||
| 688767Hangzhou Biotest BiotechLtd | CNÂ¥64.09 | -0.4% | n/a | CNÂ¥6.6b | n/a | PE6.3x | n/a | 4.7% | ||
| SIGASIGA Technologies | US$12.61 | -3.3% | 108.4% | US$913.0m | n/a | PE13.1x | E-14.6% | n/a | ||
| 500126Procter & Gamble Health | ₹4,196.55 | 2.4% | -25.7% | ₹68.9b | n/a | PE37.6x | n/a | 1.0% | ||
| 6600SciClone Pharmaceuticals (Holdings) | HK$8.48 | 2.3% | -42.3% | HK$5.9b | HK$11.86 | PE5.3x | E-8.5% | 3.9% | ||
| ITOSiTeos Therapeutics | US$20.87 | 1.5% | -17.4% | US$741.7m | US$44.60 | PE2.5x | E-44.5% | n/a | ||
| ORGOOrganogenesis Holdings | US$5.00 | 0% | -70.2% | US$645.7m | US$14.50 | PE7.6x | E8.5% | n/a | ||
| 2395Shin Nippon Biomedical Laboratories | JPÂ¥1,942.00 | -4.9% | 110.9% | JPÂ¥79.8b | JPÂ¥3,300.00 | PE11.3x | E0.1% | 2.1% |